Tag | Content |
---|
EnhancerAtlas ID | HS091-38972 |
Organism | Homo sapiens |
Tissue/cell | HepG2 |
Coordinate | chr5:130752550-130753580 |
TF binding sites/motifs | TF | JASPAR ID | Coordinate | Motif Sequence | Strand | -Log10(p-value) |
CTCF | MA0139.1 | chr5:130753143-130753162 | TGGCGCCACCTGGTGGTTC | - | 7.25 |
|
| Number of super-enhancer constituents: 2 | ID | Coordinate | Tissue/cell |
SE_08647 | chr5:130752604-130753715 | Brain_Inferior_Temporal_Lobe | SE_18240 | chr5:130751347-130753255 | CD4p_CD25-_Il17-_PMAstim_Th |
|
| Diseases: AD,Huntington,Obesity,Parkinson,Prostate cancer,Schizophrenia and Sleep disorder | Number of disease enhancers: 1 | Chromosome | Start | End |
|
| Number: 2 | ID | Chromosome | Start | End |
GH05I131416 | chr5 | 130752601 | 130752750 | GH05I131417 | chr5 | 130753061 | 130753250 |
|
Enhancer Sequence | GCATTTCATA AAAGAGGAAA TGGCCTATAG TAATATGAAA AAGGTGCTCA ACCCCACTAA 60 TAACTAGGGA AATGCAAACT AAAACCACAA TACCATTACA TACCAACCAA AATGGCCAAA 120 GTGAAAGAAG AACGCTGAAA ATACCAACTG GTCAGAACAG ATGAGAACTT GCCAGGGAGT 180 CTTTGTAATA CACAGTTGTT CAATATATAT TGTTAGACTT CTGATTTTTT TTTTTTAGTG 240 CATATTTTGT ACAGGTATGT TTTTCATTCC CATTCAGAGT TGGACCATTT GTATTTTCTG 300 GTAGGTTTCT CTTGTGGTCC CTGAAAAAAT CCAATGCTTA CTGAGTATTG CAAATCCTAT 360 GCCCACATTT ACAAACAATA TACATATTAG AGTATTGCTA ATACCATACT ATCATTCACT 420 GTTATCCAAA GATTATCCAA CTAGAACCTA AAATTCTATG ACATTTCCTG GTTTGGAAAT 480 GCTTCAATTT TGTCAAATAT TTCACTATTG GCTGCAGAAA CATCTGCAAT GACGACTAAG 540 AAATTACCTT GCTCTCTCTT TAAAAGGAGA CTTCCAAGAG TCATATTGTA GCGTGGCGCC 600 ACCTGGTGGT TCCACTGTAT CCAACGTATT TTTTTTCTTC TACCATCTCT TCCCCCTTTC 660 AGCCCTTTTC TTGTTTCTCC TCTTCCCAGG TTCATCTGCC ACTACATTCC ACATTAGACA 720 GCAGCACAGT TAACACTTCG CCATGGCCAA TTCCGAACCT ATGCAGAGTT TTACAGAATG 780 AGATAAAGCA CTTCTCTGTA TGTTTATTAG ATAATTTTTT CTTTTATGAA GTGCTTCATT 840 AAGGTTTTTG CCCATTTTTC TATTGGGTGT TCCTTTTCTT TGGTATACAG AAGTACTTTA 900 CATACCTGGA CACCTGTCCT TTGACGGTTA TATGAATTAA TATATTTCCC AACTCTACAG 960 GCTTTTTGTT TTTGTAAATG GTGTTTTTTG GTGAATGCAT TCTAGTATAG TCAAATATAT 1020 CAATCACTTC 1030
|